Browsing Pathways
Showing 81 -
90 of 605359 pathways
PathBank ID | Pathway Name and Description | Pathway Class | Chemical Compounds | Proteins |
---|---|---|---|---|
SMP0130872View Pathway |
Zanubrutinib Drug MetabolismHomo sapiens
Zanubrutinib is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Zanubrutinib passes through the liver and is then excreted from the body mainly through the kidney.
|
Metabolite
Metabolic
|
|
|
SMP0129374View Pathway |
Zanthoxylum clava-herculis whole Drug MetabolismHomo sapiens
|
Metabolite
Metabolic
|
|
|
SMP0129400View Pathway |
Zanthoxylum clava-herculis bark Drug MetabolismHomo sapiens
|
Metabolite
Metabolic
|
|
|
SMP0130196View Pathway |
Zansecimab Drug MetabolismHomo sapiens
|
Metabolite
Metabolic
|
|
|
SMP0129802View Pathway |
Zanidatamab Drug MetabolismHomo sapiens
|
Metabolite
Metabolic
|
|
|
SMP0143007View Pathway |
Zanamivir Drug Metabolism Action PathwayHomo sapiens
|
Metabolite
Drug Action
|
|
|
SMP0126040View Pathway |
Zanamivir Action PathwayHomo sapiens
Zanamivir, also known as Relenza, is an inhibitor of the viral neuraminidase protein. This antiviral is used to treat and prevent influenza A and B infections. By interacting with the neuraminidase, Zabamivir renders the influenza virus unable to escape its host cell. Neuraminidases are essential for the cleaving of the terminal sialic acids on the glycosylated HA during the virus budding to facilitate its release. In consequence, the virus will not be able to infect other cells. This molecule is available as an intravenous solution or as a powder for inhalation.
|
Metabolite
Drug Action
|
||
SMP0130189View Pathway |
Zampilimab Drug MetabolismHomo sapiens
|
Metabolite
Metabolic
|
|
|
SMP0129019View Pathway |
Zalutumumab Drug MetabolismHomo sapiens
|
Metabolite
Metabolic
|
|
|
SMP0129891View Pathway |
Zalifrelimab Drug MetabolismHomo sapiens
|
Metabolite
Metabolic
|
|
Showing 81 -
90 of 167268 pathways